A novel approach for breast cancer treatment: the multifaceted antitumor effects of rMeV-Hu191.

ABSTRACT:

Background

The therapeutic potential of oncolytic measles virotherapy has been demonstrated across various malignancies. However, the effectiveness against human breast cancer (BC) and the underlying mechanisms of the recombinant measles virus vaccine strain Hu191 (rMeV-Hu191) remain unclear.

Methods

We utilized a range of methods, including cell viability assay, Western blot, flow cytometry, immunofluorescence, SA-β-gal staining, reverse transcription quantitative real-time PCR, transcriptome sequencing, BC xenograft mouse models, and immunohistochemistry to evaluate the antitumor efficacy of rMeV-Hu191 against BC and elucidate the underlying mechanism. Additionally, we employed transcriptomics and gene set enrichment analysis to analyze the lipid metabolism status of BC ce

SUBMITTER: Zheng XY 

PROVIDER: S-EPMC11439206 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature